KU-19-19

KU-19-19 is a human bladder carcinoma cell line with distinct advantages for studying transitional cell carcinoma biology, tumor microenvironment interactions, and cytokine-mediated signaling. This epithelial cell line was established in 1993 by a Japanese research team from an invasive transitional cell carcinoma of the bladder (grade 3, pT3b) obtained from a 76-year-old male patient who exhibited marked leukocytosis. The cell line grows adherently as epithelial-like cells in monolayers under standard culture conditions, with a doubling time of approximately 48 hours.

A defining feature of KU-19-19 cells is their ability to constitutively produce and secrete multiple hematopoietic growth factors. Conditioned medium from KU-19-19 cultures contains high levels of granulocyte colony-stimulating factor (G-CSF, exceeding 5 ng/mL), as well as GM-CSF, M-CSF, stem cell factor (SCF), interleukin-6 (IL-6), and interleukin-8 (IL-8). These secreted factors vigorously stimulate proliferation of growth factor-dependent hematopoietic cell lines in a dose-dependent manner, confirming their functional biological activity. This robust secretory profile makes KU-19-19 a practical source for G-CSF purification and a versatile platform for tumor-hematopoietic cell interaction studies.

KU-19-19 cells exhibit constitutive activation of NF-κB, a transcription factor frequently dysregulated in advanced malignancies. When implanted, these cells form tumors in nude mice, associated with severe neutrophilia in peripheral blood, recapitulating the paraneoplastic leukocytosis observed in the original patient. Numerous studies have leveraged KU-19-19 cells to evaluate drug candidates such as the NF-κB inhibitor DHMEQ and natural compounds active against bladder cancer progression, demonstrating their broad utility in anticancer research.